MediPharm Labs Corp.
LABS.TO
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 30.60M | 28.71M | 27.86M | 27.43M | 24.51M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 30.60M | 28.71M | 27.86M | 27.43M | 24.51M |
| Cost of Revenue | 20.51M | 17.97M | 16.24M | 17.79M | 16.70M |
| Gross Profit | 10.09M | 10.74M | 11.62M | 9.65M | 7.81M |
| SG&A Expenses | 15.75M | 15.02M | 15.69M | 17.37M | 15.64M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -47.70K | 83.40K | -99.70K | 22.20K | 168.30K |
| Total Operating Expenses | 36.44M | 33.37M | 32.07M | 35.42M | 32.72M |
| Operating Income | -5.85M | -4.66M | -4.20M | -7.98M | -8.22M |
| Income Before Tax | -7.83M | -8.85M | -10.04M | -10.30M | -9.91M |
| Income Tax Expenses | -- | -200.70K | -202.90K | -202.90K | -202.90K |
| Earnings from Continuing Operations | -7.83 | -8.65 | -9.84 | -10.10 | -9.70 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.83M | -8.65M | -9.84M | -10.10M | -9.70M |
| EBIT | -5.85M | -4.66M | -4.20M | -7.98M | -8.22M |
| EBITDA | -3.99M | -2.74M | -2.20M | -5.99M | -6.43M |
| EPS Basic | -0.02 | -0.02 | -0.02 | -0.03 | -0.03 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.02 | -0.02 | -0.02 | -0.03 | -0.03 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 1.63B | 1.60B | 1.58B | 1.57B | 1.44B |
| Average Diluted Shares Outstanding | 1.63B | 1.60B | 1.58B | 1.57B | 1.44B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |